BAJAJ BROKING

Notification close image
No new Notification messages
card image
Seshaasai Technologies Ltd IPO
Apply for the Seshaasai Technologies Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

Piramal Pharma Q2 Results FY25–26: Net Profit, Revenue & Highlights

Adani Ports Q2 Results FY25–26: Revenue ₹9,167 Cr Up 30% YoY, Net Profit ₹3,120 Cr Up 29% YoY

Synopsis:


Piramal Pharma Limited reported consolidated revenue of ₹2,043.72 crore for Q2 FY26, down 9% YoY. The company posted a net loss of ₹99.22 crore against a profit of ₹22.59 crore in Q2 FY25, reflecting margin pressure amid lower operational income.


Source:
 Piramal Pharma Limited Board Meeting Outcome (BSE Filing) | Published on 5 Nov 2025

Piramal Pharma Limited announced its unaudited consolidated financial results for the quarter ended 30 September 2025. The company reported a decline in both revenue and profitability compared with the previous year, higher finance costs and employee expenses.

Piramal Pharma Q2 Results FY25–26 Date & Announcement

The Board of Directors of Piramal Pharma Limited approved the unaudited financial results for Q2 FY26 at its meeting held on 5 November 2025. The meeting commenced at 5:30 p.m. and concluded at 8:40 p.m.

PIRAMAL PHARMA LIMITED

Trade

199.57-0.84 (-0.41 %)

Updated - 06 November 2025
209.25day high
DAY HIGH
196.50day low
DAY LOW
11958818
VOLUME (BSE)

Piramal Pharma Q2 Results FY25–26 – Key Financial Highlights

(All figures in ₹ crore – Consolidated, Unaudited)

Particulars

Q2 FY26

Q1 FY26

Q2 FY25

Revenue from Operations

2,043.72

1,933.71

2,241.75

Other Income

65.60

58.40

61.11

Total Income

2,109.32

1,992.11

2,302.86

EBITDA (Approx.)

224.29

165.10

402.72

Finance Costs

82.42

86.15

107.64

Profit Before Tax

(46.18)

(79.02)

120.12

Net Profit / (Loss)

(99.22)

(81.70)

22.59

EPS (₹)

(0.75)

(0.62)

0.17

Note: EBITDA approximated from Total Income – Expenses + Depreciation.

Piramal Pharma Q2 FY25–26 vs Q2 FY24–25 – Comparison

(All figures in ₹ crore – Consolidated, Unaudited)

Metric

Q2 FY26

Q2 FY25

Revenue from Operations

2,043.72

2,241.75

Profit Before Tax

(46.18)

120.12

Profit After Tax

(99.22)

22.59

EPS (₹)

(0.75)

0.17

The company posted a YoY decline in revenue and moved to a net loss position due to higher employee and finance costs. Operating margins contracted amid sustained cost pressures in its pharma solutions and critical care segments.

Key Highlights – Piramal Pharma Q2 FY25–26

  • Total Income: ₹2,109.32 crore, down 8% YoY.

  • Net Loss: ₹99.22 crore vs Profit of ₹22.59 crore YoY.

  • Employee Expenses: ₹611.46 crore, up 9% YoY.

  • Finance Costs: ₹82.42 crore, down 23% YoY.

  • Depreciation & Amortisation: ₹202.84 crore, up 5% YoY.

  • Total Comprehensive Loss: ₹28.31 crore vs Income of ₹77.55 crore YoY.

  • Exceptional Gain: ₹20.74 crore recorded in Q1 FY26 from IBC settlement.

Market Reaction After Piramal Pharma Q2 Results FY25–26

The results were announced post-market hours on 5 November 2025. Piramal Pharma shares closed at ₹201.53 on the BSE, up 0.55% from the previous session, as investors assessed the impact of margin pressures against moderate revenue growth.

Conclusion – What Piramal Pharma Q2 Results Indicate

Piramal Pharma’s Q2 FY26 performance reflects continued challenges in profitability amid cost pressures and restructuring in its global operations. Sequential revenue growth was modest, but losses narrowed compared with Q1.

Disclaimer:This content has been published for informational purposes only. Bajaj Broking is not affiliated with, nor does it endorse or assume any responsibility for, the source material. Readers are advised to consult the original publication for complete and accurate context.

Frequently Asked Questions

No result found

search icon

Read More Blogs

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

11 lakh+ Users

icon-with-text

4.6 App Rating

icon-with-text

4 Languages

icon-with-text

₹6,800+ Cr MTF Book

icon-with-text
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|